October 2021 OSE Immunotherapeutics Receives Notice of Allowance for New U.S. Patent Protecting OSE-127
October 2021 OSE Immunotherapeutics Presents New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019
October 2021 OSE Immunotherapeutics Announces New Research Collaboration with Léon Bérard Cancer Center
October 2021 OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 for BI 765063